Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02352883 · ClinicalTrials.gov registry record · NA
MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ
A NA study of Ductal Breast Carcinoma in Situ, sponsored by ECOG-ACRIN Cancer Research Group.
- Active
- Registry status
- NA
- Development phase
- 368
- Enrollment target
- 20
- Study locations
NCT02352883: Active NA study of Ductal Breast Carcinoma in Situ, sponsored by ECOG-ACRIN Cancer Research Group.
NCT02352883 is a NA study of Ductal Breast Carcinoma in Situ that is active but no longer recruiting, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 368 participants, above the 118-participant average among 11 other Ductal Breast Carcinoma in Situ trials with a reported enrollment target (212% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02352883, a NA study of Ductal Breast Carcinoma in Situ, is active but no longer recruiting, sponsored by ECOG-ACRIN Cancer Research Group.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 368 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical trial studies magnetic resonance imaging (MRI) and gene expression in diagnosing patients with abnormal cells in the breast duct that have not spread outside the duct. MRI uses radio waves and a powerful magnet linked to a computer to create detailed pictures of areas inside the body. MRI may help find and diagnose patients with breast cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. Genetic studies may help doctors predict the outcome of treatment and the risk for disease recurrence. Performing MRI with genetic studies may help determine the best treatment for patients with breast cancer in situ.
Conditions Studied
Interventions
- PROCEDURE Magnetic Resonance Imaging
- RADIATION Radiation Therapy
- PROCEDURE Therapeutic Conventional Surgery
- PROCEDURE Therapeutic Surgical Procedure
- DRUG Endocrine Therapy
Study Locations (20)
Illinois
- Northwestern University - Chicago
- Ingalls Memorial Hospital - Harvey
- Edward Hospital/Cancer Center - Naperville
- Edward Hospital/Cancer Center?Plainfield - Plainfield
- Springfield Clinic - Springfield
- Memorial Medical Center - Springfield
Connecticut
- Greenwich Hospital - Greenwich
- Hartford Hospital - Hartford
- Midstate Medical Center - Meriden
- The Hospital of Central Connecticut - New Britain
Delaware
- Helen F Graham Cancer Center - Newark
- Medical Oncology Hematology Consultants PA - Newark
- Regional Hematology and Oncology PA - Newark
- Christiana Care Health System-Christiana Hospital - Newark
Indiana
- IU Health West Hospital - Avon
- Indiana University/Melvin and Bren Simon Cancer Center - Indianapolis
- Memorial Regional Cancer Center Day Road - Mishawaka
California
- Kaiser Permanente-San Diego Zion - San Diego
- Kaiser Permanente-San Marcos - San Marcos
Florida
- John Fitzgerald Kennedy Medical Center - Atlantis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 368 participants |
| Start Date | 2015-03-25 |
| Est. Completion | 2027-11 |
| Phase | NA |
What the registry record for NCT02352883 still lists
NCT02352883 is an interventional study that assigns participants to a tested intervention. The registered 368 participants enrollment target is mid-sized for trials with a published cap, above the 118-participant average among 11 other Ductal Breast Carcinoma in Situ trials with a reported enrollment target (212% higher).
The record links to 1 condition, with Ductal Breast Carcinoma in Situ appearing as the primary indexed condition, and to 5 interventions - of which Magnetic Resonance Imaging is the first listed.
NCT02352883 names 20 study sites across 6 states, led by Illinois, Connecticut, Delaware.
Frequently Asked Questions
What is clinical trial NCT02352883 about?
NCT02352883 is a clinical study titled "MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ". This clinical trial studies magnetic resonance imaging (MRI) and gene expression in diagnosing patients with abnormal cells in the breast duct that have not spread outside the duct. MRI uses radio waves and a powerful magnet linked to a computer to create detailed pictures of areas inside the body. ...
What is the current status of trial NCT02352883?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 368 participants. The study started on 2015-03-25. Estimated completion is 2027-11.
What conditions does trial NCT02352883 study?
This clinical trial studies the following conditions: Ductal Breast Carcinoma in Situ.
What interventions are being tested in trial NCT02352883?
The interventions under investigation include: Magnetic Resonance Imaging (PROCEDURE), Radiation Therapy (RADIATION), Therapeutic Conventional Surgery (PROCEDURE), Therapeutic Surgical Procedure (PROCEDURE), Endocrine Therapy (DRUG).
Who is sponsoring clinical trial NCT02352883?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02352883 being conducted?
This trial has 20 study locations across California, Connecticut, Delaware, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ductal Breast Carcinoma in Situ
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02352883's enrollment target sits among peer trials
368 1st of 11 higher than 11 of 11 other Ductal Breast Carcinoma in Situ trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ductal Breast Carcinoma in Situ trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
RECRUITING · NA
-
Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants
ACTIVE NOT RECRUITING · NA
-
Prospective Pilot Study of Robot-assisted Nipple Sparing Mastectomy (RNSM)
ACTIVE NOT RECRUITING · NA
-
5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer
RECRUITING · Phase 2
-
Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04675476 · 368 participants · NA
A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
- NCT05215353 · 368 participants · Phase 4
A Study Comparing Music Therapy and Cognitive Behavioral Therapy for Anxiety in Cancer Survivors
- NCT06182397 · 368 participants · NA
Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease
- NCT06629610 · 368 participants · NA
Diet and Active Lifestyle - Yuuyaraq (The Yup'ik Way of Life)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI